Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for MN-166 (ibudilast) in Amyotrophic lateral sclerosis. The expected timing is based on the latest available company guidance and may change.
COMBAT-ALS trial. 4/9/25- First patient enrolled in EAP trial. 7/24/25- Down to single-digit number of subjects needed randomization. Top-line data by YE 2026. 9/22/25- Enrollment completed. 12/08/25:- COMBAT-ALS randomized 234; enrollment complete Sept 2025; baseline characteristics presented; topline data expected YE 2026. 01/29/26:- SEANOBI EAP reached 100 of 200 ALS patients across 12 US sites; COMBAT-ALS topline still expected YE 2026. 07/15/26:- SEANOBI-ALS EAP enrolled 200; final follow-ups Early 2027; COMBAT-ALS topline still YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.